;PMID: 2659902
;source_file_1181.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..29] = [t:0..29]
;1)sentence:[e:34..148] = [t:34..148]
;2)section:[e:152..197] = [t:152..197]
;3)section:[e:201..274] = [t:201..274]
;4)sentence:[e:278..444] = [t:278..444]
;5)sentence:[e:445..656] = [t:445..656]
;6)sentence:[e:657..815] = [t:657..815]
;7)sentence:[e:816..936] = [t:816..936]
;8)sentence:[e:937..1079] = [t:937..1079]
;9)sentence:[e:1080..1165] = [t:1080..1165]
;10)section:[e:1169..1213] = [t:1169..1213]

;section 0 Span:0..29
;Leukemia  1989 Jul;3(7):511-5
(SEC
  (FRAG (NNP:[0..8] Leukemia) (CD:[10..14] 1989) (.:[15..21] Jul;3-LRB-)
        (CD:[21..23] 7-RRB-) (CD:[23..27] :511) (HYPH:[27..28] -)
        (CD:[28..29] 5)))

;sentence 1 Span:34..148
;c-myc amplification coexistent with activating N-ras point mutation in the 
;biphenotypic leukemic cell line RED-3.
;[34..39]:gene-rna:"c-myc"
;[40..53]:variation-type:"amplification"
;[81..86]:gene-rna:"N-ras"
;[87..101]:variation-type:"point mutation"
;[123..147]:malignancy:"leukemic cell line RED-3"
(SENT
  (NP-HLN
    (NP (NN:[34..39] c-myc) (NN:[40..53] amplification))
    (ADJP (JJ:[54..64] coexistent)
      (PP (IN:[65..69] with)
        (NP (VBG:[70..80] activating) (NN:[81..86] N-ras)
           (NN:[87..92] point) (NN:[93..101] mutation))))
    (PP-LOC (IN:[102..104] in)
      (NP
        (NP (DT:[105..108] the) (JJ:[110..122] biphenotypic)
            (JJ:[123..131] leukemic) (NN:[132..136] cell) (NN:[137..141] line))
        (NP (NN:[142..147] RED-3))))
    (.:[147..148] .)))

;section 2 Span:152..197
;Mallet MK, Mane SM, Meltzer SJ, Needleman SW.
(SEC
  (FRAG (NNP:[152..158] Mallet) (NNP:[159..161] MK) (,:[161..162] ,)
        (NNP:[163..167] Mane) (NNP:[168..170] SM) (,:[170..171] ,)
        (NNP:[172..179] Meltzer) (NNP:[180..182] SJ) (,:[182..183] ,)
        (NNP:[184..193] Needleman) (NNP:[194..197] SW.)))

;section 3 Span:201..274
;Department of Medicine, University of Maryland Hospital, Baltimore 21201.
(SEC
  (FRAG (NNP:[201..211] Department) (IN:[212..214] of) (NNP:[215..223] Medicine)
        (,:[223..224] ,) (NNP:[225..235] University) (IN:[236..238] of)
        (NNP:[239..247] Maryland) (NNP:[248..256] Hospital) (,:[256..257] ,)
        (NNP:[258..267] Baltimore) (.:[268..273] 21201) (.:[273..274] .)))

;sentence 4 Span:278..444
;While activation of the protooncogene c-N-ras is observed regularly in acute 
;myelogenous leukemia, amplification of c-myc in AML cells or derived lines is
; uncommon.
;[316..323]:gene-rna:"c-N-ras"
;[349..376]:malignancy:"acute  myelogenous leukemia"
;[378..391]:variation-type:"amplification"
;[395..400]:gene-rna:"c-myc"
;[404..407]:malignancy:"AML"
(SENT
  (S
    (SBAR-ADV (IN:[278..283] While)
      (S
        (NP-SBJ-1
          (NP (NN:[284..294] activation))
          (PP (IN:[295..297] of)
            (NP
              (NP (DT:[298..301] the) (NN:[302..315] protooncogene))
              (NP (NN:[316..323] c-N-ras)))))
        (VP (VBZ:[324..326] is)
          (VP (VBN:[327..335] observed)
            (NP-1 (-NONE-:[335..335] *))
            (ADVP-TMP (RB:[336..345] regularly))
            (PP (IN:[346..348] in)
              (NP (JJ:[349..354] acute) (JJ:[356..367] myelogenous)
                  (NN:[368..376] leukemia)))))))
    (,:[376..377] ,)
    (NP-SBJ
      (NP (NN:[378..391] amplification))
      (PP (IN:[392..394] of)
        (NP (NN:[395..400] c-myc)))
      (PP-LOC (IN:[401..403] in)
        (NP
          (NP (NN:[404..407] AML) (NNS:[408..413] cells))
          (CC:[414..416] or)
          (NP (VBN:[417..424] derived) (NNS:[425..430] lines)))))
    (VP (VBZ:[431..433] is)
      (ADJP-PRD (JJ:[435..443] uncommon)))
    (.:[443..444] .)))

;sentence 5 Span:445..656
;In particular, concurrent ras/myc activation, which has been shown to  be
;critical in several elegant models of malignancy, has been demonstrated in a 
;very small number of human tumors or derivative cell lines.
;[471..474]:gene-rna:"ras"
;[475..478]:gene-rna:"myc"
(SENT
  (S
    (PP (IN:[445..447] In)
      (NP (JJ:[448..458] particular)))
    (,:[458..459] ,)
    (NP-SBJ-3
      (NP (JJ:[460..470] concurrent)
        (NML
          (NML (NN:[471..474] ras)
            (NML-1 (-NONE-:[474..474] *P*)))
          (SYM:[474..475] /)
          (NML (NN:[475..478] myc)
            (NML-1 (NN:[479..489] activation)))))
      (,:[489..490] ,)
      (SBAR
        (WHNP-2 (WDT:[491..496] which))
        (S
          (NP-SBJ-2 (-NONE-:[496..496] *T*))
          (VP (VBZ:[497..500] has)
            (VP (VBN:[501..505] been)
              (VP (VBN:[506..511] shown)
                (S
                  (NP-SBJ-2 (-NONE-:[511..511] *))
                  (VP (TO:[512..514] to)
                    (VP (VB:[516..518] be)
                      (ADJP-PRD (JJ:[519..527] critical))
                      (PP (IN:[528..530] in)
                        (NP
                          (NP (JJ:[531..538] several) (JJ:[539..546] elegant)
                              (NNS:[547..553] models))
                          (PP (IN:[554..556] of)
                            (NP (NN:[557..567] malignancy))))))))))))))
    (,:[567..568] ,)
    (VP (VBZ:[569..572] has)
      (VP (VBN:[573..577] been)
        (VP (VBN:[578..590] demonstrated)
          (NP-3 (-NONE-:[590..590] *))
          (PP-LOC (IN:[591..593] in)
            (NP
              (NP (DT:[594..595] a)
                (ADJP (RB:[597..601] very) (JJ:[602..607] small))
                (NN:[608..614] number))
              (PP (IN:[615..617] of)
                (NP
                  (NP (JJ:[618..623] human) (NNS:[624..630] tumors))
                  (CC:[631..633] or)
                  (NP (JJ:[634..644] derivative) (NN:[645..649] cell)
                      (NNS:[650..655] lines)))))))))
    (.:[655..656] .)))

;sentence 6 Span:657..815
;A cell line, RED-3,  is described which was derived from cells of a patient
;with aggressive acute  leukemia which exhibits many markers of lineage
;infidelity.
;[670..675]:malignancy:"RED-3"
;[738..764]:malignancy:"aggressive acute  leukemia"
(SENT
  (S
    (NP-SBJ-4
      (NP
        (NP (DT:[657..658] A) (NN:[659..663] cell) (NN:[664..668] line))
        (,:[668..669] ,)
        (NP (NN:[670..675] RED-3)))
      (SBAR-1 (-NONE-:[675..675] *ICH*)))
    (,:[675..676] ,)
    (VP (VBZ:[678..680] is)
      (VP (VBN:[681..690] described)
        (NP-4 (-NONE-:[690..690] *))
        (SBAR-1
          (WHNP-3 (WDT:[691..696] which))
          (S
            (NP-SBJ-3 (-NONE-:[696..696] *T*))
            (VP (VBD:[697..700] was)
              (VP (VBN:[701..708] derived)
                (NP-3 (-NONE-:[708..708] *))
                (PP (IN:[709..713] from)
                  (NP
                    (NP (NNS:[714..719] cells))
                    (PP (IN:[720..722] of)
                      (NP
                        (NP (DT:[723..724] a) (NN:[725..732] patient))
                        (PP (IN:[733..737] with)
                          (NP
                            (NP (JJ:[738..748] aggressive) (JJ:[749..754] acute)
                                (NN:[756..764] leukemia))
                            (SBAR
                              (WHNP-2 (WDT:[765..770] which))
                              (S
                                (NP-SBJ-2 (-NONE-:[770..770] *T*))
                                (VP (VBZ:[771..779] exhibits)
                                  (NP
                                    (NP (JJ:[780..784] many)
                                        (NNS:[785..792] markers))
                                    (PP (IN:[793..795] of)
                                      (NP (NN:[796..803] lineage)
                                          (NN:[804..814] infidelity)))))))))))))))))))
    (.:[814..815] .)))

;sentence 7 Span:816..936
;DNA from this cell  line contains an activating point mutation of c-N-ras as
;well as 20-30-fold  amplification of c-myc.
;[864..878]:variation-type:"point mutation"
;[882..889]:gene-rna:"c-N-ras"
;[913..926]:variation-type:"amplification"
;[930..935]:gene-rna:"c-myc"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[816..819] DNA))
      (PP (IN:[820..824] from)
        (NP (DT:[825..829] this) (NN:[830..834] cell) (NN:[836..840] line))))
    (VP (VBZ:[841..849] contains)
      (NP
        (NP
          (NP (DT:[850..852] an) (VBG:[853..863] activating)
             (NN:[864..869] point) (NN:[870..878] mutation))
          (PP (IN:[879..881] of)
            (NP (NN:[882..889] c-N-ras))))
        (CONJP (RB:[890..892] as) (RB:[893..897] well) (IN:[898..900] as))
        (NP
          (NP
            (QP
              (QP (CD:[901..903] 20) (HYPH:[903..904] -) (CD:[904..906] 30))
              (HYPH:[906..907] -) (JJ:[907..911] fold))
            (NN:[913..926] amplification))
          (PP (IN:[927..929] of)
            (NP (NN:[930..935] c-myc))))))
    (.:[935..936] .)))

;sentence 8 Span:937..1079
;After HL-60, this is the second example of ras/myc  activation in AML derived
;cells and demonstrates that this lesion is not unique  to HL-60.
;[943..948]:malignancy:"HL-60"
;[980..983]:gene-rna:"ras"
;[984..987]:gene-rna:"myc"
;[1003..1006]:malignancy:"AML"
;[1043..1054]:malignancy:"this lesion"
;[1073..1078]:malignancy:"HL-60"
(SENT
  (S
    (PP (IN:[937..942] After)
      (NP (NN:[943..948] HL-60)))
    (,:[948..949] ,)
    (NP-SBJ (DT:[950..954] this))
    (VP
      (VP (VBZ:[955..957] is)
        (NP-PRD
          (NP (DT:[958..961] the) (JJ:[962..968] second) (NN:[969..976] example))
          (PP (IN:[977..979] of)
            (NP
              (NP (NN:[980..983] ras)
                (NML-1 (-NONE-:[983..983] *P*)))
              (SYM:[983..984] /)
              (NP (NN:[984..987] myc)
                (NML-1 (NN:[989..999] activation))))))
        (PP-LOC (IN:[1000..1002] in)
          (NP
            (ADJP (NN:[1003..1006] AML) (VBN:[1007..1014] derived))
            (NNS:[1015..1020] cells))))
      (CC:[1021..1024] and)
      (VP (VBZ:[1025..1037] demonstrates)
        (SBAR (IN:[1038..1042] that)
          (S
            (NP-SBJ (DT:[1043..1047] this) (NN:[1048..1054] lesion))
            (VP (VBZ:[1055..1057] is)
              (ADJP-PRD (RB:[1058..1061] not) (JJ:[1062..1068] unique)
                (PP (TO:[1070..1072] to)
                  (NP (NN:[1073..1078] HL-60)))))))))
    (.:[1078..1079] .)))

;sentence 9 Span:1080..1165
;Rather, it may be important in leukemogenesis in a small proportion of  AML
;patients.
;[1152..1155]:malignancy:"AML"
(SENT
  (S
    (ADVP (RB:[1080..1086] Rather))
    (,:[1086..1087] ,)
    (NP-SBJ (PRP:[1088..1090] it))
    (VP (MD:[1091..1094] may)
      (VP (VB:[1095..1097] be)
        (ADJP-PRD (JJ:[1098..1107] important))
        (PP (IN:[1108..1110] in)
          (NP (NN:[1111..1125] leukemogenesis)))
        (PP-LOC (IN:[1126..1128] in)
          (NP
            (NP (DT:[1129..1130] a) (JJ:[1131..1136] small)
                (NN:[1137..1147] proportion))
            (PP (IN:[1148..1150] of)
              (NP (NN:[1152..1155] AML) (NNS:[1156..1164] patients)))))))
    (.:[1164..1165] .)))

;section 10 Span:1169..1213
;PMID: 2659902 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1169..1173] PMID) (::[1173..1174] :) (CD:[1175..1182] 2659902)
        (IN:[1183..1184] -LSB-) (NNP:[1184..1190] PubMed) (HYPH:[1191..1192] -)
        (JJ:[1193..1200] indexed) (IN:[1201..1204] for)
        (NNP:[1205..1213] MEDLINE-RSB-)))
